Cargando…
Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides
Pharmacological modulation of p53 activity is an attractive therapeutic strategy in cancers with wild-type p53. Presently in clinical trials, the small molecule Nutlin-3A competitively binds to HDM2, a key negative regulator of p53 and blocks its activity. We have described resistance mutations in H...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835680/ https://www.ncbi.nlm.nih.gov/pubmed/24278380 http://dx.doi.org/10.1371/journal.pone.0081068 |